Javier Torrens, MD
Endocrinology, Diabetes & Metabolism · Summit, NJNPI 1578555298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,860 of the $102,703 with a category attached, or 93.3%. 37 manufacturers reported payments, led by Novo Nordisk at 56.8% of the total. Reporting peaked in 2019 at $34,960 and has fallen 97.2% since, to $975 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $288.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$58K
- Boehringer Ingelheim$13K
- AstraZeneca$12K
- Merck$10K
- Lilly USA, LLC$6K
- Amgen$432
- plus $2K from 31 others
What the payments were for
- Consulting fees$6001%
- Speaking & faculty fees$95,86093%
- Travel & lodging$3000%
- Food & beverage$5,9176%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 120 | $58,320 |
| Boehringer Ingelheim | 24 | $13,414 |
| AstraZeneca | 17 | $12,371 |
| Merck | 15 | $9,626 |
| Lilly USA, LLC | 34 | $6,390 |
| Amgen | 29 | $432 |
| Dexcom, Inc. | 11 | $280 |
| Bayer | 11 | $229 |
| Xeris Pharmaceuticals, Inc. | 11 | $181 |
| Johnson & Johnson | 12 | $165 |
| Medtronic | 7 | $153 |
| Sanofi-aventis U.S. LLC | 9 | $147 |
| AbbVie | 9 | $144 |
| Abbott | 7 | $140 |
| IBSA Pharma Inc. | 6 | $90 |
| Tandem Diabetes Care, Inc. | 3 | $65 |
| Cequr Corporation | 2 | $64 |
| Mannkind Corporation | 3 | $54 |
| Valeritas, Inc. | 2 | $52 |
| Corcept Therapeutics | 3 | $45 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Vivus LLC | 2 | $31 |
| Lifescan, Inc. | 2 | $30 |
| Pfizer | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Embecta Corp. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| BD | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,703 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $188,704 |
| JardianceEmpagliflozin | 83 | $93,264 |
| MounjaroTirzepatide | 51 | $69,050 |
| JanuviaSitagliptin Phosphate | 55 | $58,317 |
| TrulicityDulaglutide | 41 | $54,934 |
| FarxigaDapagliflozin Propanediol | 46 | $43,624 |
| SynthroidLevothyroxine Sodium | 384 | $38,660 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $22,211 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $19,266 |
| TradjentaLinagliptin | 15 | $13,758 |
| Levothyroxine Sodium | 676 | $6,954 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $6,883 |
| VascepaIcosapent Ethyl | 14 | $5,067 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $4,572 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 50 | $4,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $58,320 | $188,704113 claims |
| Lilly USA, LLCMounjaro, Trulicity | $6,390 | $123,98492 claims |
| Boehringer IngelheimJardiance, Tradjenta | $13,414 | $107,02398 claims |
| MerckJanuvia | $9,626 | $58,31755 claims |
| AstraZenecaFarxiga | $12,371 | $43,62446 claims |
| AbbVieSynthroid, Armour Thyroid | $144 | $40,694398 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $34 | $6,954676 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Summit
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.